Researchers at Leipzig University and Martin Luther University Halle-Wittenberg have investigated a previously unknown ...

The Nobel Prize in Medicine was awarded on Monday to three scientists for discovering how a particular kind of cell can stop ...

In this phase 3, multinational, randomized, double-blind trial, we examined the safety and efficacy of once-daily orforglipron at doses of 6 mg, 12 mg, or 36 mg, as compared with placebo (assigned in ...

Researchers at Ruhr University Bochum, Germany, identified a receptor that plays a crucial role in stress-induced motor ...

Anti-obesity drugs such as semaglutide (Ozempic, Wegovy) are also promising for the treatment of alcohol use disorder and alcohol-associated liver disease, as growing evidence suggests they reduce the ...

Glycemic, weight, cardiometabolic outcomes improved for children and teens with obesity, prediabetes, or T2D. HealthDay News — In children and adolescents with type 2 diabetes (T2D) or obesity, ...

VIENNA — Adults with obesity but without diabetes who took the investigational, oral GLP-1 receptor agonist orforglipron for 72 weeks lost significantly more weight than those on placebo, according to ...

"Type 2 diabetes in children and teens is increasing at an alarming rate, yet treatment options are limited, and this patient population remains underserved," said Kenneth Custer, Ph.D., executive ...

Eli Lilly and Company announced detailed results from SURPASS-PEDS, the first phase 3 trial to evaluate the safety and efficacy of Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, in ...

Complete 26-week results further demonstrate that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped prevent about half of semaglutide-induced loss of lean mass, while increasing ...